FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367309418> ?p ?o ?g. }

• W4367309418 endingPage "e0281257" @default.
• W4367309418 startingPage "e0281257" @default.
• W4367309418 abstract "Background Identifying a specific threshold level of SARS-CoV-2 antibodies that confers protection in immunocompromised patients has been very challenging. The aim was to assess the threshold of 264 binding antibody units (BAU)/ml using four different SARS-CoV-2 antibody assays (Abbott, Beckman, Roche, and Siemens) and to establish a new optimal threshold of protection for each of the four antibody assays. Methods This study was performed on data retrieved from 69 individuals, who received at least one dose of the Pfizer/BioNTech BNT162b2 or Moderna COVID-19 vaccine (Spikevax) at the Alphabio Laboratory in Marseille, France (European Hospital, Alphabio–Biogroup). The results were compared to the percent inhibition calculated using a functional surrogate of a standardized virus neutralization test (Genscript). Results Samples from 69 patients were analyzed. For a reference cutoff of 264 BAU/ml, assays showed moderate to good overall concordance with Genscript: 87% concordance for Abbott, 78% for Beckman, 75% for Roche, and 88% for Siemens. Overall concordance increased consistently after applying new thresholds, i.e., 148 BAU/ml (Abbott), 48 (Beckman), 559 (Roche), and 270 (Siemens). Conclusion We suggest specific adjusted thresholds (BAU/ml) for the four commercial antibody assays that are used to assess pre-exposure prophylaxis in immunocompromised patients." @default.
• W4367309418 created "2023-04-29" @default.
• W4367309418 creator A5008119645 @default.
• W4367309418 creator A5012480967 @default.
• W4367309418 creator A5014920295 @default.
• W4367309418 creator A5015391181 @default.
• W4367309418 creator A5015714125 @default.
• W4367309418 creator A5016809605 @default.
• W4367309418 creator A5025326750 @default.
• W4367309418 creator A5027107191 @default.
• W4367309418 creator A5037880774 @default.
• W4367309418 creator A5063371313 @default.
• W4367309418 creator A5079072445 @default.
• W4367309418 creator A5082869296 @default.
• W4367309418 creator A5084321788 @default.
• W4367309418 creator A5084527353 @default.
• W4367309418 creator A5089241061 @default.
• W4367309418 date "2023-04-28" @default.
• W4367309418 modified "2023-10-18" @default.
• W4367309418 title "Anti-spike protein to determine SARS-CoV-2 antibody levels: Is there a specific threshold conferring protection in immunocompromised patients?" @default.
• W4367309418 cites W2009637031 @default.
• W4367309418 cites W2064086456 @default.
• W4367309418 cites W3021431926 @default.
• W4367309418 cites W3087633667 @default.
• W4367309418 cites W3097740956 @default.
• W4367309418 cites W3108193091 @default.
• W4367309418 cites W3110499570 @default.
• W4367309418 cites W3122043911 @default.
• W4367309418 cites W3143243833 @default.
• W4367309418 cites W3151746440 @default.
• W4367309418 cites W3164547793 @default.
• W4367309418 cites W3173738234 @default.
• W4367309418 cites W3174017401 @default.
• W4367309418 cites W3174317300 @default.
• W4367309418 cites W3190574993 @default.
• W4367309418 cites W4210350488 @default.
• W4367309418 cites W4210574644 @default.
• W4367309418 cites W4210747912 @default.
• W4367309418 cites W4225492884 @default.
• W4367309418 cites W4226119706 @default.
• W4367309418 cites W4226236687 @default.
• W4367309418 cites W4281660188 @default.
• W4367309418 cites W4281768377 @default.
• W4367309418 cites W4303672095 @default.
• W4367309418 doi "https://doi.org/10.1371/journal.pone.0281257" @default.
• W4367309418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37115758" @default.
• W4367309418 hasPublicationYear "2023" @default.
• W4367309418 type Work @default.
• W4367309418 citedByCount "1" @default.
• W4367309418 countsByYear W43673094182023 @default.
• W4367309418 crossrefType "journal-article" @default.
• W4367309418 hasAuthorship W4367309418A5008119645 @default.
• W4367309418 hasAuthorship W4367309418A5012480967 @default.
• W4367309418 hasAuthorship W4367309418A5014920295 @default.
• W4367309418 hasAuthorship W4367309418A5015391181 @default.
• W4367309418 hasAuthorship W4367309418A5015714125 @default.
• W4367309418 hasAuthorship W4367309418A5016809605 @default.
• W4367309418 hasAuthorship W4367309418A5025326750 @default.
• W4367309418 hasAuthorship W4367309418A5027107191 @default.
• W4367309418 hasAuthorship W4367309418A5037880774 @default.
• W4367309418 hasAuthorship W4367309418A5063371313 @default.
• W4367309418 hasAuthorship W4367309418A5079072445 @default.
• W4367309418 hasAuthorship W4367309418A5082869296 @default.
• W4367309418 hasAuthorship W4367309418A5084321788 @default.
• W4367309418 hasAuthorship W4367309418A5084527353 @default.
• W4367309418 hasAuthorship W4367309418A5089241061 @default.
• W4367309418 hasBestOaLocation W43673094181 @default.
• W4367309418 hasConcept C116675565 @default.
• W4367309418 hasConcept C126322002 @default.
• W4367309418 hasConcept C159047783 @default.
• W4367309418 hasConcept C159654299 @default.
• W4367309418 hasConcept C160798450 @default.
• W4367309418 hasConcept C203014093 @default.
• W4367309418 hasConcept C2779134260 @default.
• W4367309418 hasConcept C2909509916 @default.
• W4367309418 hasConcept C2909597000 @default.
• W4367309418 hasConcept C3006700255 @default.
• W4367309418 hasConcept C3007834351 @default.
• W4367309418 hasConcept C3008058167 @default.
• W4367309418 hasConcept C40993552 @default.
• W4367309418 hasConcept C524204448 @default.
• W4367309418 hasConcept C71924100 @default.
• W4367309418 hasConceptScore W4367309418C116675565 @default.
• W4367309418 hasConceptScore W4367309418C126322002 @default.
• W4367309418 hasConceptScore W4367309418C159047783 @default.
• W4367309418 hasConceptScore W4367309418C159654299 @default.
• W4367309418 hasConceptScore W4367309418C160798450 @default.
• W4367309418 hasConceptScore W4367309418C203014093 @default.
• W4367309418 hasConceptScore W4367309418C2779134260 @default.
• W4367309418 hasConceptScore W4367309418C2909509916 @default.
• W4367309418 hasConceptScore W4367309418C2909597000 @default.
• W4367309418 hasConceptScore W4367309418C3006700255 @default.
• W4367309418 hasConceptScore W4367309418C3007834351 @default.
• W4367309418 hasConceptScore W4367309418C3008058167 @default.
• W4367309418 hasConceptScore W4367309418C40993552 @default.
• W4367309418 hasConceptScore W4367309418C524204448 @default.
• W4367309418 hasConceptScore W4367309418C71924100 @default.
• W4367309418 hasIssue "4" @default.

• next